CEACAM 1,5,6,8 antibody
CEACAM1/3/5/8
Reactivity: Human
WB, cELISA, FACS, IHC (fro), ELISA
Host: Mouse
Monoclonal
TET2
unconjugated
(1 reference)-
- Target
- CEACAM 1,5,6,8 (CEACAM1/3/5/8) (Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1/3/5/8 (CEACAM1/3/5/8))
- Reactivity
- Human
- Host
- Mouse
- Clonality
- Monoclonal
- Application
- Western Blotting (WB), Cell-ELISA (cELISA), Flow Cytometry (FACS), Immunohistochemistry (Frozen Sections) (IHC (fro)), ELISA
- Specificity
- Anti-human CEACAM1,5,6,8 (CD66a,b,c,e)
- Purification
- Protein G
- Immunogen
- immunisation with extracted protein of CEACAM5
- Clone
- TET2
- Isotype
- IgG2b
-
- Application Notes
-
Flow cytometry: 1 µg/10^6 cells
ELISA: 1:200 - 1:400
CELISA: 1:200 Western Blot: 4 µg/mL
Immunohistology: 1-2 µg/10^6 cells (on cryosections)
For each application a titration should be performed to determine the optimal concentration. - Comment
-
Synonyms: CD66abce
- Restrictions
- For Research Use only
-
- Concentration
- 1 mg/mL
- Buffer
- PBS, pH 7.2
- Handling Advice
- Avoid repeated freezing and thawing.
- Storage
- 4 °C
- Storage Comment
- short term: 2 °C - 8 °C, long term: -20 °C
-
-
: "Differential glycosylation of MUC1 and CEACAM5 between normal mucosa and tumour tissue of colon cancer patients." in: International journal of cancer. Journal international du cancer, (2011) (PubMed).
-
: "Differential glycosylation of MUC1 and CEACAM5 between normal mucosa and tumour tissue of colon cancer patients." in: International journal of cancer. Journal international du cancer, (2011) (PubMed).
-
- Target
- CEACAM 1,5,6,8 (CEACAM1/3/5/8) (Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1/3/5/8 (CEACAM1/3/5/8))
- Alternative Name
- CEACAM1,5,6,8
- Background
- TET2 was generated by immunisation with CEA partially purified from a perchloric acid extract from liver metastases of colonic tumors. TET2 is a broadly reactive antibody which reacts with most of the CEACAM molecules characterised to date.
- UniProt
- P06731, P31997, P13688, P40199
-
You are here:
